Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hurni

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
The Journal of Biological Chemistry|September 19, 2002
Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine designJoseph G Joyce, William M Hurni, Michael J Bogusky, et al.
Biochemistry|March 19, 2003
HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAbG B McGaughey, M Citron, R C Danzeisen, et al.
Current HIV Research|April 14, 2004
Progress towards the development of a HIV-1 gp41-directed vaccineGeorgia B McGaughey, Gaetano Barbato, Elisabetta Bianchi, et al.
Protein Expression and Purification|December 22, 1999
Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiaeJ C Cook, J G Joyce, H A George, et al.
Mayo Clinic Proceedings|November 15, 2000
A prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: the SIMA trial. Stenting vs Internal Mammary ArteryJ J Goy, U Kaufmann, D Goy-Eggenberger, et al.
The Journal of Infectious Diseases|November 14, 1997
Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeastR S Lowe, D R Brown, J T Bryan, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
The Journal of Biological Chemistry|September 19, 2002
Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine designJoseph G Joyce, William M Hurni, Michael J Bogusky, et al.
Biochemistry|March 19, 2003
HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAbG B McGaughey, M Citron, R C Danzeisen, et al.
Current HIV Research|April 14, 2004
Progress towards the development of a HIV-1 gp41-directed vaccineGeorgia B McGaughey, Gaetano Barbato, Elisabetta Bianchi, et al.
Protein Expression and Purification|December 22, 1999
Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiaeJ C Cook, J G Joyce, H A George, et al.
Mayo Clinic Proceedings|November 15, 2000
A prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: the SIMA trial. Stenting vs Internal Mammary ArteryJ J Goy, U Kaufmann, D Goy-Eggenberger, et al.
The Journal of Infectious Diseases|November 14, 1997
Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeastR S Lowe, D R Brown, J T Bryan, et al.
Pageof 9